Monoclonal antibodies are already a pillar of cancer therapy, and cancer makes up the largest indication of FDA-approved antibodies, with almost 40% of the total. At the 2021 European Society of Medical Oncology (ESMO) Congress, Elena Garralda predicted that engineered versions of classical antibodies will soon join them on their pedestal.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Agenus, Alpha Cancer, Astrazeneca, Boehringer, Bridge, Corcept, Daiichi, Deciphera, Eqrx, Gritstone, Imcheck, Janssen, Junshi, Novartis, Tachyon, TCR2, Tilt.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Acepodia, Aileron, Allarity, Amgen, Athenex, Ayala, Bayer, Beyondspring, Bioxcel, Carrick, Exelixis, Gilead, Instil, Laekna, Leap, Macrogenics, Medigene, Medivir, NGM, Nouscom, Oncologie, Psioxus, Second Genome, Shasqi, Silverback, Targovax, Transgene, Zymeworks.
The European Society for Medical Oncology Congress 2021 has begun with a mix of education and multidisciplinary sessions in addition to symposia. Silverback Therapeutics Inc. was a presenter and took a hit on the market Sept. 16 with its interim phase I/Ib study results showing SBT-6050’s proof of mechanism was established with activated myeloid and T/natural killer cells when treating advanced or metastatic HER2-expressing solid tumors.
DUBLIN – Allarity Therapeutics A/S plans to file an NDA with FDA for dovitinib in renal cell carcinoma (RCC) in the fourth quarter this year, after unveiling a new analysis at the European Society for Molecular Oncology’s virtual congress, which suggest that its companion diagnostic, DRP, can identify patients who obtain a survival benefit from the therapy.
New and updated preclinical and clinical data to be presented by biopharma firms at the European Society for Medical Oncology Congress 2021, including: Adaptimmune, Boehringer Ingelheim, BMS, Cantargia, Harbour, Leap, Ose, Samsung Bioepis, Zymeworks.
The discovery of synthetic lethality between BRCA mutations and PARP inhibitors ranks has led to major advances in the treatment of BRCA-mutated cancers. Mutations in BRCA1 and BRCA2 can leave cells with a deficiency in homologous repair (HR). And that deficiency can make them vulnerable to PARP inhibitors, which block alternate DNA repair pathways, as well as platinum-based treatment, which induces DNA mutations that BRCA-deficient cells are unable to cope with.
"Nothing is undruggable!" was the bold claim at the European Society of Medical Oncology Targeted Anticancer Therapies Virtual Congress 2021 the (ESMO-TAT).
HONG KONG – New data from Beigene Ltd. recently presented at the ESMO Virtual Congress 2020 showed its PARP inhibitor pamiparib helped shrink tumors in almost 65% of people with platinum-sensitive ovarian cancer treated with the candidate during a pivotal trial.
HONG KONG – New data from Beigene Ltd. recently presented at the ESMO Virtual Congress 2020 showed its PARP inhibitor pamiparib helped shrink tumors in almost 65% of people with platinum-sensitive ovarian cancer treated with the candidate during a pivotal trial.
RSS
